AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Lung Cancer Therapeutics Market 2019-2023 | Advent of Regenerative Therapies to Boost Growth | Technavio

April 4, 2019
The global lung cancer therapeutics market will post a CAGR of over 13% during the period 2019-2023 (Graphic: Business Wire)

LONDON--(BUSINESS WIRE)--Apr 4, 2019--The global lung cancer therapeutics market is expected to post a CAGR of over 13% during the period 2019-2023, according to the latest market research report by Technavio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190404005024/en/

The global lung cancer therapeutics market will post a CAGR of over 13% during the period 2019-2023 (Graphic: Business Wire)

Lung cancer is one of the most common types of cancer. Owing to factors such as increasing geriatric population and lifestyle changes, new cases of cancer, especially lung cancer, have risen significantly in recent years. Also, the mortality rate of lung cancer is still significantly very high, which creates a huge opportunity for vendors in the market. The increasing need for treatment along with advances in therapeutics such as immunotherapy and chemotherapy is leading the growth of the global lung cancer therapeutics market.

As per Technavio, the advent of regenerative therapies will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global lung cancer therapeutics market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global lung cancer therapeutics market: Advent of regenerative therapies

The global lung cancer therapeutics market is undergoing various technological changes to develop more advanced treatment options. Currently, chemotherapy, immunomodulators, and other biological drugs are the only treatment options available in the market for the treatment of NSCLC and SCLC. Even though targeted therapies such as immunomodulators are highly effective in the treatment of lung cancer, the use of these drugs does not entirely ensure the cure of these indications. To overcome the increasing prevalence of lung cancer and to cure the indication, various vendors are focusing on developing regenerative therapies such as gene therapies. Currently, various studies are being conducted in vitro and in vivo on genes for the treatment of lung cancer. These therapies are currently in the early stages of development, and research is being conducted to ensure the development of treatments with no adverse effects. Such advances in research are expected to contribute significantly to the growth of the global lung cancer therapeutics market.

“Along with the advent of regenerative therapies, the increasing number of patient assistance programs is one other factor that is driving the growth of the global market. The drugs in the global lung cancer therapeutics market are priced high due to the heavy R&D costs. Hence, the governments of various countries have launched patient assistance programs to reduce the high-cost burden associated with lung cancer. Several initiatives are being undertaken by various organizations to help the patients to receive treatment on time,” says a senior analyst at Technavio.



Global lung cancer therapeutics market: Segmentation analysis

This market research report segments the global lung cancer therapeutics market by product (non-small-cell lung cancer and small-cell lung cancer) and geographical regions (North America, Europe, Asia, and ROW).

The North American region led the market in 2018, followed by Europe, Asia, and ROW respectively. However, during the forecast period, Asia is expected to register the highest incremental growth due to the increasing number of awareness campaigns by government organizations and vendors.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario


About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005024/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 04/04/2019 10:02 AM/DISC: 04/04/2019 10:02 AM

http://www.businesswire.com/news/home/20190404005024/en